Posted by Michael Wonder on 16 Apr 2025
Scilex announces approval of a new drug submission from the Health Canada for Elyxyb’s acute treatment of migraine with or without aura in Canada
15 April 2025 - Elyxyb is a first-line treatment and the only FDA approved, ready to use oral solution for the acute treatment of migraine, with or without aura, in adults.
Scilex today announced that it has received approval of a new drug submission from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for Elyxyb’s acute treatment of migraine with or without aura in Canada.
